ArticleClinical and vaccine immunology : CVI2008

Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects.

David M Koelle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.